FORMULATION ARTICLES

  • Is The mRNA Payload The Real MVP of Targeted Delivery?

    As one delightfully colorful quote from a panel discussion at the AMM Ascent meeting last fall reminds us, there’s a lot more to be explored, discussed, and understood as it relates to the mRNA cargo’s role in targeted delivery. 

  • Learning From Oligos: Delivery & Clinical Strategies For mRNA Therapeutics

    Those of us who attended the Alliance for mRNA Medicines’ inaugural Ascent conference last fall had the opportunity to hear from Zdravka Medarova of TransCode Therapeutics on her experiences working in the oligo sector. Here, I summarize some of her learnings and/or suggestions for the encoding RNA field as we set out to develop mRNA therapeutics for oncology.

  • Courtroom Clash: Inside The High-Stakes World Of mRNA Patent Litigation

    Here, Shores provides the “who’s who” and “what’s what” behind some of the hottest legal cases to hit the headlines in the mRNA space to-date, as well as why these cases are or could be significant to companies commercializing mRNA products in the future.

  • IP Considerations For Early-Stage mRNA Therapeutics Development

    Fortunately, navigating the patent landscape is hardly a “doomsday” scenario. But it is a challenge biotechs need to tackle early so they don’t end up too far down the path toward the clinic or in the clinic mired with delays and expensive litigation. Here, Rothwell Figg partner Dan Shores shares several strategies companies may choose to employ when facing a legal gray area to protect their products from patent litigation upon commercialization.

  • A Primer On The RNA Patent Landscape

    In the first- of this three-part article, Shores gives us an important primer on the RNA legal landscape as it stands today. As many of us are working on crafting the next generation of mRNA/RNA products and LNPs, I wanted to get his sense of how our continued scientific advancement is likely to impact the IP landscape in the long-term.

  • Tune Therapeutics' 2025 Epigenome Editing Outlook

    Chief Scientific Officer Derek Jantz talks about recent key innovations in gene therapy and RNA technology while considering what milestones we might see in 2025.

FORMULATION VIDEOS

In this video, Russell Johnson, VP Formulation Research for RVAC Medicines, and Aalok Shah, Director of Formulation & Drug Delivery for Strand Therapeutics, outline several examples of foundational research that could provide insights into how we attain more specific cellular uptake of LNPs.

Discover how revolutionary and environmentally sustainable nanoparticle technologies coupled with innovative formulation approaches can address drug solubility issues and add value for patients.

Unlock the power of data-driven bioprocessing. Discover how advanced analytics can optimize your cell culture process, improve performance, and accelerate success.

As the RNA-LNP space continues to diversify beyond linear mRNA and infectious disease vaccines, Kate Zhang of Hopewell Therapeutics, Sumit Luthra of Sanofi, and Ben Muir of BioNTech each address several misconceptions about LNP composition today and how the rise of novel RNA modalities, more advanced mechanisms of action, and novel lipids are challenging our understanding of/work with LNPs today.

ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS